Eleven-year survivor of unresectable intrahepatic cholangiocarcinoma treated using long-term UFT therapy.
We report a 49-year-old man with unresectable intrahepatic cholangiocarcinoma (ICC) who was treated with oral tegafur-uracil (UFT) chemotherapy and survived for over a decade. In 1995, the patient was admitted to our institution after a large tumor in his left liver was detected using computed tomography (CT). The tumor was diagnosed as ICC, and a laparotomy was performed; however, the tumor was too advanced to perform a curative resection. The cancer had spread to the lymph nodes in the hepatoduodenal ligament and on the posterior surface of the pancreas head. A curative resection was abandoned, and oral UFT chemotherapy was started immediately after the laparotomy. The tumor remained almost unchanged until 2001 with only UFT administration; however, its size gradually increased to 7.8 cm in diameter. External-beam radiotherapy (50.4 Gy) was performed, and the tumor's size decreased to 6.3 cm in diameter. Eleven years have now passed since the laparotomy, and the patient continues to lead a normal daily life working as a banker. The cumulative dose of UFT has reached 2511 g without any significant adverse effects. This case suggests that oral UFT might suppress the progression of ICC, contributing to this patient's 11-year survival period.
Takemura
Nobuyuki
N
Department of Surgery, Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Graduate School of Medicine, University of Tokyo, Japan. takemuranobu-tky@umin.ac.jp
Kokudo
Norihiro
N
Imamura
Hiroshi
H
Takazawa
Yutaka
Y
Sano
Keiji
K
Sugawara
Yasuhiko
Y
Nakagawa
Keiichi
K
Ohtomo
Kuni
K
Makuuchi
Masatoshi
M
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality* / Q000532:radiotherapy; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D008297:Male; D011879:Radiotherapy Dosage; D017741:Survivors; D005641:Tegafur / Q000008:administration & dosage*
D000964:Antimetabolites, Antineoplastic; D005641:Tegafur